Plenary speakers

Every year, we invite a number of plenary speakers who are experts in their respective fields. Their talks complement the Symposium sessions by providing a coherent overview on a variety of topics across the ALS/MND research and clinical management spectrum. Click on the images below to find out more about the plenary speakers who will be presenting at the Virtual 32nd International Symposium on ALS/MND. Please note, sessions are provisional so may be subject to change.

DAY 1 - TUESDAY 7 DECEMBER 2021

SESSION 1 - OPENING SESSION

The Stephen Hawking Memorial Lecture
Dr Jennifer Doudna

Innovative Genomics Institute, USA

SESSION 2 - CLINICAL TRIALS

Dr Angela Genge
Montreal Neurological Institute and Hospital, Canada

DAY 2 - WEDNESDAY 8 DECEMBER 2021

SESSION 3 - METABOLISM AND NUTRITION

Prof Chris McDermott
University of Sheffield, England

SESSION 4 - CELL BIOLOGY & PATHOLOGY

Prof Julie Atkin
Macquarie Centre for MND Research, Australia

SESSION 5 - AUTONOMY AND DECISION MAKING

Dr Heike Gudat
Hospiz im Park, Switzerland

DAY 3 - THURSDAY 9 DECEMBER 2021

SESSION 6 - DISEASE MODELS

Prof Lorenz Studer
Memorial Sloan Kettering Cancer Center, USA

SESSION 7 - TRANSLATING RESEARCH FROM BENCH TO BEDSIDE

Prof Jackie Hunter
BenevolentAI, England

Prof Robert Bowser
Barrow Neurological Institute, USA

Dr Ronenn Roubenoff
Novartis Institutes for Biomedical Research, USA

DAY 4 - FRIDAY 10 DECEMBER 2021

SESSION 8 - COGNITIVE CHANGE

Prof Sharon Abrahams
University of Edinburgh, Scotland

SESSION 9 - CLINICAL MANAGEMENT

Prof Orla Hardiman
Trinity College Dublin, Ireland

SESSION 10 - CLOSING SESSION

Dr Lucie Bruijn
Novartis, Switzerland

Mr Steve Gleason
Team Gleason & Answer ALS, USA